CMS proposes CY 2027 Physician Fee Schedule rule covering

Cresthaven Analytics Intelligence Brief

Headline

CMS proposes CY 2027 Physician Fee Schedule rule covering payment rates, drug inflation rebates, and shared savings updates

Executive Summary

CMS published a proposed rule on July 16, 2026 addressing calendar year 2027 payment policies under the Physician Fee Schedule, Medicare Part B, the Medicare Shared Savings Program, and the Medicare Prescription Drug Inflation Rebate Program. The proposal codifies provisions of the Inflation Reduction Act and the Consolidated Appropriations Act, 2026, and updates payment rates across multiple Part B service categories.

Bottom Line

The proposed rule opens the formal comment period for CY 2027 payment policy across the full Part B ecosystem, covering physician practices, ACOs, drug manufacturers, ambulatory facilities, RHCs, FQHCs, and clinical laboratories. Codification of the Inflation Reduction Act drug inflation rebate framework and the Consolidated Appropriations Act, 2026 provisions moves those statutory requirements into binding regulatory text for the first time. The Ambulatory Specialty Model introduction creates a new participation decision for eligible specialty and ambulatory providers. Every affected entity's reimbursement rates, quality reporting obligations, and alternative payment model participation terms are subject to change under the final rule that follows this proposal.

Key Regulatory Signals

Physician Fee Schedule Rate Revisions: CMS proposes updated relative value units and conversion factor adjustments for CY 2027, reflecting changes in medical practice and statutory requirements. Physician practices, group practices, and independent clinicians billing under Part B must assess how revised work, practice expense, and malpractice RVUs affect their reimbursement across service lines.
Drug Inflation Rebate Program Codification: The proposal codifies new policies for the Medicare Prescription Drug Inflation Rebate Program under the Inflation Reduction Act of 2022. Manufacturers of Part B drugs whose prices have risen faster than inflation face rebate liability, and this codification formalizes the program's operational and compliance framework.
Ambulatory Specialty Model Introduction: CMS proposes establishment of the Ambulatory Specialty Model, a new payment and care delivery structure. Eligible specialty practices and ambulatory facilities must evaluate participation criteria, financial benchmarks, and quality reporting obligations specific to this model.
Medicare Shared Savings Program Updates: Accountable Care Organizations operating under the Medicare Shared Savings Program face proposed changes to participation requirements, benchmarking methodology, and quality performance standards for performance year 2027. ACOs must assess whether proposed benchmark revisions alter their projected shared savings or loss exposure.
Quality Payment Program and Promoting Interoperability Revisions: CMS proposes updates to Merit-based Incentive Payment System scoring, Advanced APM thresholds, and Promoting Interoperability performance category requirements. Eligible clinicians and groups subject to MIPS payment adjustments in 2027 must evaluate whether proposed measure and threshold changes affect their performance year 2026 reporting strategy.
Rural Health Clinic and FQHC Payment Policy Changes: The proposal includes updates to payment policies for Rural Health Clinics and Federally Qualified Health Centers, including all-inclusive rate and visit policy adjustments. RHCs and FQHCs must review proposed rate and billing policy changes for operational and revenue cycle impact.

Regulatory Delta

- CMS issues an annual PFS proposed rule each July. This cycle goes further: it marks the first codification of Inflation Reduction Act drug inflation rebate provisions into the Part B payment framework, a structural addition beyond prior annual updates.

- The Ambulatory Specialty Model is a new care delivery and payment vehicle absent from the CY 2026 PFS final rule. Its introduction expands CMS's alternative payment model portfolio.

- The Consolidated Appropriations Act, 2026 provisions codified here reflect Congressional action taken after the CY 2026 rulemaking cycle closed. This rule is the first vehicle to operationalize those statutory changes.

Materiality Classification

HIGH — Sector-wide proposed rulemaking with direct reimbursement, quality reporting, and alternative payment model consequences for every Medicare Part B participant, including physician practices, ACOs, drug manufacturers, ambulatory facilities, RHCs, FQHCs, and clinical laboratories; comment period requires timely response from all affected entities.

Intelligence Outlook

Monitor the Federal Register and CMS rulemaking portal for the close of the comment period, any CMS listening sessions, and publication of the CY 2027 Physician Fee Schedule final rule expected in November 2026.